Cairn Therapeutics to Present at MedInvest Biotech & Pharma Investor Conference

March 29, 2024 06:46 AM AEDT | By EIN Presswire

Google News:

Cairn Therapeutics to Present at MedInvest Biotech & Pharma Investor Conference — Image source: EIN Presswire

Recent News

Caterpillar’s E&T segment is likely a core driver to the next EPS cycl...

Ro& by Armatec Global Appoints Former U.S. Air Force Lieutenant Genera...

Entergy Recognized as Civic 50 Honoree for the 10th Consecutive Year

Riot Platforms: Needham sees ’major opportunity’ in Corsicana

WILMINGTON, DE, USA, March 28, 2024 /EINPresswire.com/ -- Cairn Therapeutics, Inc., (“Cairn” or the “Company”), a pharmaceutical company developing highly targeted medications for the treatment of cancer, today announced that it will present an update on the company’s flagship product, CT-262, at the MedInvest Biotech & Pharma Investor Conference. Cairn’s CEO, W. Scott Evangelista and COO, Tom Fritz, will present and host one-on-one meetings at the conference being held at the Cooley offices in New York City on April 3-4, 2024. For more information about the conference, see here.

About Cairn Therapeutics
Cairn Therapeutics, Inc. is a pharmaceutical company with a mission to help patients beat cancer. Founded in 2016, Cairn is developing its lead candidate, CT-262, a first-in-its-class treatment for solid and hematological tumors. Cairn holds the exclusive worldwide license to CT-262, which was invented at Scripps Research Institute using unique medicinal chemistry to create a highly potent DNA alkylating agent that preferentially activates in cancer cells. In vitro and in vivo animal oncology studies have shown CT-262 to produce markedly better efficacy and safety results compared to current first-line therapies in these nonclinical models, and highlight the potential to replace these compounds in a broad array of cancers. Cairn intends to file an IND and begin First-in-Human trials this year. For more information, visit www.cairntherapeutics.com.

Sutton Faller
Cairn Therapeutics, Inc.
email us here

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.